Keywords: Diagnosis/Prediction, Radiomics
Motivation: Magnetic resonance imaging (MRI) raidomics has shown unique advantages and potential in non-invasive evaluation of therapeutic efficacy in cancer patients.
Goal(s): To construct a model that can predict the prognosis of patients with advanced non-small cell lung cancer (NSCLC) brain metastases after radiotherapy.
Approach: For patients with advanced NSCLC brain metastasis who underwent pre-treatment MRI examination, stable and reproducible raidomics features were quantitatively extracted and screened. Additionally, artificial intelligence methods were utilized to construct raidomics labels.
Results: The potential of the MRI raidomics-based method in predicting the efficacy of radiotherapy for brain metastases from advanced NSCLC was preliminarily confirmed.
Impact: The method based on MRI raidomics (T1, T2, DWI, DCE) can not only enhance the precision of radiation therapy efficacy assessment for patients with NSCLC brain metastasis, but also offer clinicians a more scientific basis for treatment decision-making.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords